当前位置： SCI文献检索 > ALIMENTARY PHARMACOLOGY & THERAPEUTICS期刊下所有文献 > Flumecinol for the treatment of pruritus associated with primary biliary cirrhosis.

Flumecinol for the treatment of pruritus associated with primary biliary cirrhosis.

Abstract：

OBJECTIVE:To determine whether flumecinol (3-trifluoromethyl-alpha-ethylbenzhydrol, Zixoryn) is effective in ameliorating pruritus of cholestasis, particularly in primary bilary cirrhosis. METHODS AND RESULTS:50 patients (46 with primary biliary cirrhosis, PBC) took oral flumecinol 600 mg or identical placebo once weekly for 3 weeks. Patients assessed pruritus by scoring a daily 100 mm visual analogue scale (VAS; 0 = no itch, 100 = severe, continuous, day and night intolerable itch). Quality of life was similarly measured. Patients scored the VAS daily for a 7-day baseline and for a further 21 days. Subjectively, pruritus improved in 13 of 24 on flumecinol and 10 of 26 on placebo (chi 2 = 1.24, P = 0.27). Median difference in fall in VAS pruritus score between baseline week (mean score for each individual used) and the last week was 8.0 [95% confidence interval (CI) -2.1 to 20.8] and for VAS quality of life was 5.0 (95% Cl 0.4 to 13.0) both in favour of flumecinol over placebo. Later, 19 patients (all PBC) were randomised to flumecinol 300 mg or placebo daily for 3 weeks. Subjectively, pruritus improved in 7 of 10 on flumecinol and 1 of 9 on placebo (Fisher's exact test, P = 0.02). Median difference in fall in VAS pruritus score was 19.8 mm (95% CI 3.3 to 40.7 mm) in favour of flumecinol over placebo and for quality of life was 3.5 mm (95% Cl -5.9 to 24.9 mm). Flumecinol did not significantly affect liver function tests, antipyrine clearance or serum total bile acids, and was not associated with any significant side-effects. CONCLUSION:Flumecinol was safe at the above doses and short term treatment with 300 mg daily, significantly ameliorated pruritus in primary biliary cirrhosis.

journal_name

Aliment Pharmacol Ther

journal_title

Alimentary pharmacology & therapeutics

authors

Turner IB,Rawlins MD,Wood P,James OF

doi

10.1111/j.1365-2036.1994.tb00297.x

subject

Has Abstract

pub_date

1994-06-01 00:00:00

pages

337-42

issue

3

eissn

0269-2813

issn

1365-2036

journal_volume

8

pub_type

临床试验,杂志文章,随机对照试验

相关文献

ALIMENTARY PHARMACOLOGY & THERAPEUTICS文献大全
  • Localization of the beta(beta)3-adrenoceptor in the human gastrointestinal tract: an immunohistochemical study.

    abstract：BACKGROUND:Activation of human and non-human colonic beta(beta)3-adrenoceptors causes smooth muscle relaxation. beta3-Adrenoceptor agonists protect against experimental indomethacin-induced jejunal ulceration. The mechanism of protection may involve spasmolytic/vasodilatory agonist activity. The precise localization of...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1046/j.1365-2036.1998.00345.x

    authors： Anthony A,Schepelmann S,Guillaume JL,Strosberg AD,Dhillon AP,Pounder RE,Wakefield AJ

    更新日期：1998-06-01 00:00:00

  • Use of acid-suppressive therapy before anti-reflux surgery in 2922 patients: a nationwide register-based study in Denmark.

    abstract：BACKGROUND:Guidelines recommend that patients with gastro-oesophageal reflux disease are adequately treated with acid-suppressive therapy before undergoing anti-reflux surgery. Little is known of the use of acid-suppressive drugs before anti-reflux surgery. AIM:To determine the use of proton pump inhibitors and H2 -re...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.13230

    authors： Lødrup A,Pottegård A,Hallas J,Bytzer P

    更新日期：2015-07-01 00:00:00

  • Nutritional management of patients with acute pancreatitis: a Dutch observational multicentre study.

    abstract：BACKGROUND:Following a nil per os (NPO) regimen, most patients with acute pancreatitis (AP) can resume normal oral intake within 1 week. If not tolerated, it is recommended to initiate artificial feeding, preferably by the enteral route. AIM:To evaluate the nutritional management of patients with AP in a Dutch cohort ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,多中心研究

    doi：10.1111/j.1365-2036.2008.03814.x

    authors： Spanier BW,Mathus-Vliegen EM,Tuynman HA,Van der Hulst RW,Dijkgraaf MG,Bruno MJ,EARL Study Group.

    更新日期：2008-11-01 00:00:00

  • NSAID-induced antral ulcers are associated with distinct changes in mucosal gene expression.

    abstract：BACKGROUND:The basis for individual variation in gastroduodenal vulnerability to NSAIDs is not well understood. AIM:To assess whether a gene expression signature is associated with susceptibility to gastroduodenal ulcerations. METHODS:Twenty-five Helicobacter pylori negative adults were treated for 7 days with naprox...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2036.2009.04000.x

    authors： Desai JC,Goo T,Fukata M,Sanyal S,Dikman A,Miller K,Cohen L,Brooks A,Wang Q,Abreu MT,Aisenberg J

    更新日期：2009-07-01 00:00:00

  • Octreotide in the prevention of pancreatic injury associated with endoscopic cholangiopancreatography.

    abstract：BACKGROUND:Data on whether long-acting somatostatin analogue octreotide causes or prevents pancreatic injury following endoscopic retrograde cholangiopancreatography (ERCP) are controversial. AIM:This multicentre, prospective trial studied the effect of octreotide on pancreatic injury in a large unselected group of pa...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：10.1046/j.1365-2036.1998.00414.x

    authors： Tulassay Z,Döbrönte Z,Prónai L,Zágoni T,Juhász L

    更新日期：1998-11-01 00:00:00

  • Review article: the global emergence of Helicobacter pylori antibiotic resistance.

    abstract：BACKGROUND:Helicobacter pylori is one of the most prevalent global pathogens and can lead to gastrointestinal disease including peptic ulcers, gastric marginal zone lymphoma and gastric carcinoma. AIM:To review recent trends in H. pylori antibiotic resistance rates, and to discuss diagnostics and treatment paradigms. ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/apt.13497

    authors： Thung I,Aramin H,Vavinskaya V,Gupta S,Park JY,Crowe SE,Valasek MA

    更新日期：2016-02-01 00:00:00

  • Serum pepsinogen and gastrin levels in HIV-positive patients: relationship with CD4+ cell count and Helicobacter pylori infection.

    abstract：BACKGROUND:The relationship between serum parameters of gastric function and Helicobacter pylori infection in human immunodeficiency virus (HIV)-positive patients is almost unknown. AIMS:To investigate in HIV-infected patients: (i) the relationship between serum gastrin and serum pepsinogens over the progressive phase...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1046/j.1365-2036.2002.01234.x

    authors： Fabris P,Pilotto A,Bozzola L,Tositti G,Soffiati G,Manfrin V,de Lalla F

    更新日期：2002-04-01 00:00:00

  • Oral xylose isomerase decreases breath hydrogen excretion and improves gastrointestinal symptoms in fructose malabsorption - a double-blind, placebo-controlled study.

    abstract：BACKGROUND:Incomplete resorption of fructose results in increased colonic hydrogen production and is a frequent cause of abdominal symptoms. The only treatment available is diet. AIM:To study whether orally administered xylose isomerase (XI), an enzyme that catalyses the reversible isomerisation of glucose and fructos...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,随机对照试验

    doi：10.1111/apt.12057

    authors： Komericki P,Akkilic-Materna M,Strimitzer T,Weyermair K,Hammer HF,Aberer W

    更新日期：2012-11-01 00:00:00

  • Review article: intestinal failure.

    abstract：:Intestinal failure is a specific disease entity resulting from intestinal resection or disease-associated malabsorption and characterized by the inability to maintain protein-energy, fluid, electrolyte or micronutrient balance. We performed a MEDLINE search (1966-2006) to identify relevant articles, using keywords int...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/j.1365-2036.2006.02941.x

    authors： Lal S,Teubner A,Shaffer JL

    更新日期：2006-07-01 00:00:00

  • Barriers to hepatitis C treatment in the era of direct-acting anti-viral agents.

    abstract：BACKGROUND:Direct-acting anti-virals (DAA) are safe, effective treatment of hepatitis C virus (HCV). Suboptimal linkage to specialists and access to DAAs are the leading barriers to treatment; however, data are limited. AIM:To determine predictors of follow-up, receipt of DAAs, and reasons for the lack thereof. METHO...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.14328

    authors： Lin M,Kramer J,White D,Cao Y,Tavakoli-Tabasi S,Madu S,Smith D,Asch SM,El-Serag HB,Kanwal F

    更新日期：2017-11-01 00:00:00

  • Effect of ursodeoxycholic acid administration in patients with acute viral hepatitis: a pilot study.

    abstract：BACKGROUND:Ursodeoxycholic acid (UDCA) is able to improve biochemical markers of cholestasis, with a parallel decrease in transaminases, in various cholestatic liver diseases. AIM:To evaluate the effects of UDCA administration on acute viral hepatitis-related cholestasis and the course of acute viral hepatitis. METHO...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1046/j.1365-2036.1999.00592.x

    authors： Fabris P,Tositti G,Mazzella G,Zanetti AR,Nicolin R,Pellizzer G,Benedetti P,de Lalla F

    更新日期：1999-09-01 00:00:00

  • The cost effectiveness of Helicobacter pylori population screening-economic evaluation alongside a randomised controlled trial with 13-year follow-up.

    abstract：BACKGROUND:Helicobacter pylori eradication improves dyspeptic symptoms in 8%-10%, prevents peptic ulcer and may reduce the risk of gastric cancer. Availability of a high quality diagnostic test and an effective treatment makes population screening and eradication of Helicobacter pylori an attractive option. AIM:To eva...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,随机对照试验

    doi：10.1111/apt.15193

    authors： Høgh MB,Kronborg C,Hansen JM,Schaffalitzky de Muckadell OB

    更新日期：2019-04-01 00:00:00

  • Analysis of the cag pathogenicity island and IS605 of Helicobacter pylori strains isolated from patients with gastric cancer in Japan.

    abstract：BACKGROUND:CagA protein is encoded by the cagA gene, which is part of the cag pathogenicity island (PAI) in Helicobacter pylori. Insertion sequence (IS) elements are a diverse set of specialized DNA segments that can move to new sites in bacterial genomes. AIM:To determine the role of cagPAI and IS605 in the developme...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2036.2004.01982.x

    authors： Deguchi R,Igarashi M,Watanabe K,Takagi A

    更新日期：2004-07-01 00:00:00

  • Most Helicobacter pylori strains of Kolkata in India are resistant to metronidazole but susceptible to other drugs commonly used for eradication and ulcer therapy.

    abstract：BACKGROUND:Helicobacter pylori infection is very common in India, as in other developing countries, but few data exist on the susceptibility of H. pylori to antimicrobial agents commonly used for eradication here. AIM:To determine the antimicrobial susceptibility of H. pylori strains from Kolkata, in eastern India. M...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2036.2005.02533.x

    authors： Datta S,Chattopadhyay S,Patra R,De R,Ramamurthy T,Hembram J,Chowdhury A,Bhattacharya SK,Berg DE,Nair GB,Mukhopadhyay AK

    更新日期：2005-07-01 00:00:00

  • Review article: gastroparesis.

    abstract：BACKGROUND:Gastroparesis is a chronic disorder caused by stomach pump failure and characterized by profound nausea, vomiting and epigastric pain. Most often, the cause is unapparent and of the known associations, diabetes is the most common. Diagnosis is usually made using an isotope-labelled test meal. Treatment is in...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1111/j.1365-2036.2008.03637.x

    authors： Patrick A,Epstein O

    更新日期：2008-05-01 00:00:00

  • Mycophenolate mofetil in refractory inflammatory bowel disease.

    abstract：BACKGROUND:Mycophenolate mofetil has been claimed to be effective and well tolerated in refractory inflammatory bowel disease although there is little information regarding its use in clinical practice. AIM:To review our experience in achieving and maintaining remission in refractory inflammatory bowel disease and to ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1046/j.1365-2036.2003.01581.x

    authors： Ford AC,Towler RJ,Moayyedi P,Chalmers DM,Axon AT

    更新日期：2003-06-01 00:00:00

  • Clinico-biochemical prediction of biliary cause of acute pancreatitis in the era of endoscopic ultrasonography.

    abstract：BACKGROUND:Occult biliary stones escape detection on conventional investigations, and clinico-biochemical systems proposed for predicting biliary pancreatitis has low predictive values. AIM:To evaluate the accuracy of clinico-biochemical parameters for prediction of biliary pancreatitis in patients undergoing endoscop...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2036.2005.02580.x

    authors： Liu CL,Fan ST,Lo CM,Tso WK,Wong Y,Poon RT,Lam CM,Wong BC,Wong J

    更新日期：2005-09-01 00:00:00

  • Microbial translocation and T cell activation are modified by direct-acting antiviral therapy in HCV-infected patients.

    abstract：BACKGROUND:Microbial translocation from the gut lumen has been involved in the pathogenesis of liver damage in hepatitis C virus (HCV) infection. AIM:To investigate the impact of direct-acting antiviral treatment on microbial translocation and T-cell activation, in patients with hepatitis C-related liver disease. MET...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.14994

    authors： Lattanzi B,Baroncelli S,De Santis A,Galluzzo CM,Mennini G,Michelini Z,Lupo M,Ginanni Corradini S,Rossi M,Palmisano L,Merli M

    更新日期：2018-11-01 00:00:00

  • Review article: the management of severe Crohn's disease.

    abstract：:The treatment of severe and active Crohn's disease is currently based on immunosuppression, but also involves the management of nutrition, appropriate selection of patients for surgery, and maintenance of remission in the long term. Corticosteroids remain the drug of the first choice, particularly in the acute setting...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,评审

    doi：10.1046/j.1365-2036.2001.00963.x

    authors： Parkes M,Jewell DP

    更新日期：2001-05-01 00:00:00

  • Diastolic dysfunction on echocardiography does not predict survival after transjugular intrahepatic portosystemic stent-shunt in patients with cirrhosis.

    abstract：BACKGROUND:Cardiac dysfunction is frequently observed in patients with cirrhosis. There remains a paucity of data from routine clinical practice regarding the role of echocardiography in the pre-assessment of transjugular intrahepatic portosystemic stent-shunt. AIM:Our study aimed to investigate if echocardiography pa...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.15164

    authors： Armstrong MJ,Gohar F,Dhaliwal A,Nightingale P,Baker G,Greaves D,Mangat K,Zia Z,Karkhanis S,Olliff S,Mehrzad H,Steeds RP,Tripathi D

    更新日期：2019-03-01 00:00:00

  • Effects of baseline abdominal pain and bloating on response to lubiprostone in patients with irritable bowel syndrome with constipation.

    abstract：BACKGROUND:Lubiprostone (8 μg b.d.) received US Food and Drug Administration (FDA) approval in 2008 for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) in women aged ≥18 years. In 2012, the FDA issued new guidance for IBS-C clinical trials, recommending a composite endpoint incorporating both...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,随机对照试验

    doi：10.1111/apt.13807

    authors： Chang L,Chey WD,Drossman D,Losch-Beridon T,Wang M,Lichtlen P,Mareya S

    更新日期：2016-11-01 00:00:00

  • Comparative assessment of phenolphthalein and phenolphthalein glucuronide: is phenolphthalein glucuronide a better laxative?

    abstract：BACKGROUND:Phenolphthalein is widely used as a safe and effective laxative. After oral administration, phenolphthalein is absorbed in the small bowel and is conjugated in the liver to phenolphthalein glucuronide which passes into the colon where it is deconjugated and the active compound, phenolphthalein, is released. ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1111/j.1365-2036.1994.tb00331.x

    authors： Anand BS,Torres E,Operkun A,Graham DY

    更新日期：1994-10-01 00:00:00

  • Faecal microbiota transplantation plus selected use of vancomycin for severe-complicated Clostridium difficile infection: description of a protocol with high success rate.

    abstract：BACKGROUND:Severe and severe/complicated Clostridium difficile infection (CDI) can result in ICU admission, sepsis, toxic megacolon and death. In this setting, colectomy is the standard of care but it is associated with a 50% mortality. AIM:To evaluate safety and efficacy of a sequential faecal microbiota transplantat...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.13290

    authors： Fischer M,Sipe BW,Rogers NA,Cook GK,Robb BW,Vuppalanchi R,Rex DK

    更新日期：2015-08-01 00:00:00

  • Effects of midazolam on small bowel motility in humans.

    abstract：BACKGROUND:Benzodiazepines are used as sedatives for some intestinal procedures and as hypnotics, and this is the reason for studying their effects on duodenojejunal motility. METHODS:Antroduodenojejunal manometry was performed in 13 healthy volunteers on two different occasions, when placebo or midazolam were given i...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1046/j.1365-2036.2000.00741.x

    authors： Castedal M,Björnsson E,Abrahamsson H

    更新日期：2000-05-01 00:00:00

  • Comparison of the effects of intravenously and orally administered esomeprazole on acid output in patients with symptoms of gastro-oesophageal reflux disease.

    abstract：BACKGROUND:Intravenous esomeprazole may be beneficial for patients who cannot take oral medications. AIM:To compare intravenous esomeprazole with oral esomeprazole for effects on maximal acid output during pentagastrin stimulation in patients with gastro-oesophageal reflux disease symptoms. METHODS:In four separate o...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1111/j.1365-2036.2005.02659.x

    authors： Metz DC,Miner PB,Heuman DM,Chen Y,Sostek M

    更新日期：2005-11-01 00:00:00

  • Citric acid-enhanced Helicobacter pylori urease activity in vivo is unrelated to gastric emptying.

    abstract：BACKGROUND:In a previous study, the use of a citric acid test meal produced a rapid dose-dependent increase in urease activity that was significantly greater than that resulting from a pudding meal, ascorbic acid or sodium citrate. The mechanism was hypothesized to be related to the ability of citric acid to delay gast...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1046/j.1365-2036.2001.01096.x

    authors： Shiotani A,Saeed A,Yamaoka Y,Osato MS,Klein PD,Graham DY

    更新日期：2001-11-01 00:00:00

  • Ranitidine bismuth citrate with clarithromycin versus omeprazole with amoxycillin in the cure of Helicobacter pylori infection.

    abstract：AIM:To compare the efficacy of ranitidine bismuth citrate plus clarithromycin (RBC-C) vs. omeprazole plus amoxycillin (OME-AMO) in the cure of Helicobacter pylori infection. METHODS:In this double-blind, multicentre, parallel-group study 122 H. pylori-positive patients with active duodenal ulcer or gastritis, with con...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 临床试验,杂志文章,多中心研究,随机对照试验

    doi：10.1046/j.1365-2036.1997.00254.x

    authors： Kolkman JJ,Tan TG,Oudkerk Pool M,Van Kleef WA,Geraedts AA,Timmerman RJ,Crobach LF,Nicolai JJ,Wolff AA,Van Der Laan J

    更新日期：1997-12-01 00:00:00

  • Patterns and predictors of mortality and disease progression among patients with non-alcoholic fatty liver disease.

    abstract：BACKGROUND:Factors associated with mortality and disease progression in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are poorly understood. AIMS:To assess the impact of liver disease severity, demographics and comorbidities on all-cause mortality and liver disease progression in a...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.16016

    authors： Canbay A,Kachru N,Haas JS,Sowa JP,Meise D,Ozbay AB

    更新日期：2020-10-01 00:00:00

  • New onset idiosyncratic liver enzyme elevations with biological therapy in inflammatory bowel disease.

    abstract：BACKGROUND:Anti-tumour necrosis factor α (anti-TNF) agents have been implicated in drug-induced liver injury. There is minimal data on this occurrence in inflammatory bowel disease (IBD) patients. AIM:To identify the characteristics of liver enzyme elevations following anti-TNF therapy initiation in IBD. METHODS:A re...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/apt.13159

    authors： Shelton E,Chaudrey K,Sauk J,Khalili H,Masia R,Nguyen DD,Yajnik V,Ananthakrishnan AN

    更新日期：2015-05-01 00:00:00

  • A novel diagnostic tool for detecting oesophageal pathology: the PillCam oesophageal video capsule.

    abstract：BACKGROUND:Gastro-oesophageal reflux disease is a common entity. Erosive oesophagitis, ulcers and Barrett's oesophagus, which is found in up to 10% of gastro-oesophageal reflux disease patients, characterize severe gastro-oesophageal reflux disease. Patients with Barrett's oesophagus have 0.5% per patient-year risk of ...

    journal_title：Alimentary pharmacology & therapeutics

    pub_type： 杂志文章

    doi：10.1111/j.1365-2036.2004.02206.x

    authors： Eliakim R,Yassin K,Shlomi I,Suissa A,Eisen GM

    更新日期：2004-11-15 00:00:00